Multibagger Stock Alert: Specialty Chemical Stock Hits 52-Week High; Delivers 400% Return in 2 Yrs

Sudarshan Pharma Industries shares touched a fresh 52-week high on the BSE on Tuesday after the company said its board would consider a proposal to raise funds on 18 June 2026. The stock rose as much as 2.23% to ₹38.00 in early trade, extending its winning run to a seventh straight session, before slipping into the red as investors booked profits at higher levels.

The move drew attention because the small-cap counter has already seen a sharp rally across recent time frames. The proposed fundraise, if approved, may give the company additional capital through equity, warrants, convertible securities, debt securities or a combination of these instruments. However, such proposals also matter for shareholders because they can affect ownership structure, liquidity and future capital allocation.

Sudarshan Pharma share price reacts to fundraising plan

In a regulatory filing dated 15 June, Sudarshan Pharma Industries said its board would meet on Thursday, 18 June 2026, to consider and approve a fundraising proposal. The company said the funds may be raised through private placement, preferential issue, qualified institutions placement or other permitted methods, subject to necessary approvals.

The board is also expected to consider related actions needed to complete the fundraising process. These may include approvals required under company law, securities regulations and stock exchange rules. The filing did not specify the exact size of the proposed fundraise, the likely investors, the purpose of the funds or the final structure of the issue.

At 11:25 am, Sudarshan Pharma share price was trading 2.04% lower at ₹36.41 on the BSE. The reversal showed that traders were using the sharp rise to lock in gains, even as the broader trigger remained the company's capital-raising plan. In small-cap stocks, such moves can be sharper because trading volumes and investor participation are often less stable than in large-cap names.

For existing shareholders, the key question will be the form in which the company raises money. A preferential issue or qualified institutions placement may increase the number of shares in circulation. Debt securities, on the other hand, may avoid immediate equity dilution but can add repayment obligations. The final impact will depend on pricing, terms and the stated use of proceeds.

Recent warrant conversion adds to investor focus

The latest fundraising plan comes shortly after a warrant-related allotment to promoter-category investors. On 12 June, the Warrants Committee of the company's board approved the allotment of 90 lakh equity shares with a face value of Re 1 each. These shares were allotted at an issue price of ₹16.983 each following the conversion of 9 lakh warrants.

The warrants had been issued at ₹169.83 each to persons belonging to the promoter category on a preferential basis. The company said it received the balance amount of ₹11.46 crore, calculated at ₹127.37 per warrant, representing 75% of the issue price per warrant. The allotment followed the exercise of conversion rights by the warrant holders.

Warrant conversions are watched closely by the market because they increase the paid-up equity base once converted into shares. They can also indicate confidence from the allottees, especially when they are from the promoter category. At the same time, investors usually assess whether the expanded share capital changes earnings per share, promoter holding patterns or the stock's valuation comfort.

The timing of the board meeting has therefore become significant. The company has completed one capital-related action and is now preparing to consider another. Until the board announces the final structure, investors may continue to react to expectations rather than confirmed details. This can increase short-term volatility, particularly after a strong price run.

Multibagger stock has rallied sharply

Sudarshan Pharma share price has gained more than 21% in one month and 56% in three months. Over six months, the stock has risen 47%, while the one-year gain stands at 24%. The longer-term performance is more striking, with the shares delivering multibagger returns of about 400% in two years and 438% over three years.

The proposed fundraise may become a key marker for the next phase of the stock's movement. If the company discloses a clear purpose, such as expansion, working capital, debt reduction or strategic investment, the market may evaluate the plan against its balance sheet and growth prospects. If details remain limited, price action may stay driven by momentum and trading sentiment.